Company licensing deal valuation
One of the prerequisites of biopharmaceutical licensing negotiations is understanding the possible licensing deal structures available and the financial impact of different deal arrangements. Furthermore, understanding the financial impact of upfront, milestone payments, royalties and equity on licensing deals can also be useful benchmark tools in the licensing negotiation process, presentations to potential investors and business plan preparations.
We have created the PharmaPlus Deal Financials – Company2 database, which since 1996 focuses on licensing deal financials for not yet registered therapeutics between biopharmaceutical companies.
Our database solely displays licensing deals for which at least one financial component (potential deal size, upfront, milestones, research funding, profit sharing, royalties, equity) is available. Next to these financial components our database offers information as far as available on compound class, compound name, disease area and/or indications covered, development stage at deal closure and licensed territory.
Customized list of benchmark deals
We can provide you with a list of benchmark deals from our PharmaPlus Deal Financials – Company2 database, tailored specifically to your needs, with a minimum of 5 and a maximum of 25 licensing deals at USD 20 per deal / € 18 per deal.
We invite you to contact us to discuss your enquiry.